This issue of Cardiology Clinics, edited by Dr. Stephen Nicholls, focuses on Lipidology. Topics include, but are not limited to: Impact of lipoproteins on atherobiology; Lessons from genomic studies; Lipids and lipoproteins in risk prediction; Optimizing statins and ezetimibe in guideline focused management; Statin intolerance; Lipid lowering agents and diabetes risk; PCSK9 inhibitors; Bempedoic Acid; Triglyceride rich lipoproteins; Omega 3 Fatty Acids; Lipoprotein; CETP inhibitors; HDL infusions; and Targeting HDL functionality.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Impact of Lipoproteins on Atherobiology: Emerging Insights - p. 193 9. Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies - p. 203 10. Lipids and Lipoproteins in Risk Prediction - p. 213 11. Optimizing Statins and Ezetimibe in Guideline-Focused Management - p. 221 12. Statin Intolerance: Some Practical Hints - p. 225 13. Treating Dyslipidemia in Type 2 Diabetes - p. 233 14. Proprotein Convertase Subtilisin Kexin 9 Inhibitors - p. 241 15. Bempedoic Acid (ETC-1002): A Current Review - p. 257 16. Triglyceride-Rich Lipoproteins - p. 265 17. Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia - p. 277 18. Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic? - p. 287 19. Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk - p. 299 20. High-Density Lipoprotein Infusions - p. 311 21. High-Density Lipoproteins: Effects on Vascular Function and Role in the Immune Response - p. 317 22. Intravascular Ultrasound Studies of Plaque Progression and Regression: Impact of Lipid-Modifying Therapies - p. 329
No hay muestra disponible
No hay ficha técnica disponible
This issue of Cardiology Clinics, edited by Dr. Stephen Nicholls, focuses on Lipidology. Topics include, but are not limited to: Impact of lipoproteins on atherobiology; Lessons from genomic studies; Lipids and lipoproteins in risk prediction; Optimizing statins and ezetimibe in guideline focused management; Statin intolerance; Lipid lowering agents and diabetes risk; PCSK9 inhibitors; Bempedoic Acid; Triglyceride rich lipoproteins; Omega 3 Fatty Acids; Lipoprotein; CETP inhibitors; HDL infusions; and Targeting HDL functionality.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. xi 7. Preface - p. xiii 8. Impact of Lipoproteins on Atherobiology: Emerging Insights - p. 193 9. Causal Effect of Lipids and Lipoproteins on Atherosclerosis: Lessons from Genomic Studies - p. 203 10. Lipids and Lipoproteins in Risk Prediction - p. 213 11. Optimizing Statins and Ezetimibe in Guideline-Focused Management - p. 221 12. Statin Intolerance: Some Practical Hints - p. 225 13. Treating Dyslipidemia in Type 2 Diabetes - p. 233 14. Proprotein Convertase Subtilisin Kexin 9 Inhibitors - p. 241 15. Bempedoic Acid (ETC-1002): A Current Review - p. 257 16. Triglyceride-Rich Lipoproteins - p. 265 17. Evolution of Omega-3 Fatty Acid Therapy and Current and Future Role in the Management of Dyslipidemia - p. 277 18. Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic? - p. 287 19. Cholesteryl Ester Transfer Protein Inhibitors as Agents to Reduce Coronary Heart Disease Risk - p. 299 20. High-Density Lipoprotein Infusions - p. 311 21. High-Density Lipoproteins: Effects on Vascular Function and Role in the Immune Response - p. 317 22. Intravascular Ultrasound Studies of Plaque Progression and Regression: Impact of Lipid-Modifying Therapies - p. 329
No hay muestra disponible
No hay ficha técnica disponible
